TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) just unveiled an update.
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its trastuzumab biosimilar, Dazublys®, intended for treating HER2-positive breast cancers. This endorsement marks an important step for Aurobindo Pharma in strengthening its biosimilars portfolio, with expectations for European Commission approval by July, furthering its commitment to launching at least ten biosimilars by 2030 to enhance cancer care and address unmet patient needs.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited, through its subsidiary CuraTeQ Biologics, is a global biopharmaceutical company based in Hyderabad, India, focusing on developing biosimilars for cancer and autoimmune diseases. The company aims to provide high-quality, cost-effective therapies with a pipeline of fourteen biosimilars targeting immunology and oncology segments.
YTD Price Performance: -6.94%
Average Trading Volume: 34,176
Current Market Cap: 730.4B INR
For an in-depth examination of AUROPHARMA stock, go to TipRanks’ Stock Analysis page.